These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

172 related items for PubMed ID: 12231519

  • 1. Results of a Phase I dose-escalating study of the antiangiogenic agent, SU5416, in patients with advanced malignancies.
    Stopeck A, Sheldon M, Vahedian M, Cropp G, Gosalia R, Hannah A.
    Clin Cancer Res; 2002 Sep; 8(9):2798-805. PubMed ID: 12231519
    [Abstract] [Full Text] [Related]

  • 2. Phase II study of the antiangiogenic agent SU5416 in patients with advanced soft tissue sarcomas.
    Heymach JV, Desai J, Manola J, Davis DW, McConkey DJ, Harmon D, Ryan DP, Goss G, Quigley T, Van den Abbeele AD, Silverman SG, Connors S, Folkman J, Fletcher CD, Demetri GD.
    Clin Cancer Res; 2004 Sep 01; 10(17):5732-40. PubMed ID: 15355900
    [Abstract] [Full Text] [Related]

  • 3. Phase II study of SU5416--a small-molecule, vascular endothelial growth factor tyrosine-kinase receptor inhibitor--in patients with refractory myeloproliferative diseases.
    Giles FJ, Cooper MA, Silverman L, Karp JE, Lancet JE, Zangari M, Shami PJ, Khan KD, Hannah AL, Cherrington JM, Thomas DA, Garcia-Manero G, Albitar M, Kantarjian HM, Stopeck AT.
    Cancer; 2003 Apr 15; 97(8):1920-8. PubMed ID: 12673719
    [Abstract] [Full Text] [Related]

  • 4. A phase II, pharmacokinetic, and biologic study of semaxanib and thalidomide in patients with metastatic melanoma.
    Mita MM, Rowinsky EK, Forero L, Eckhart SG, Izbicka E, Weiss GR, Beeram M, Mita AC, de Bono JS, Tolcher AW, Hammond LA, Simmons P, Berg K, Takimoto C, Patnaik A.
    Cancer Chemother Pharmacol; 2007 Feb 15; 59(2):165-74. PubMed ID: 16736151
    [Abstract] [Full Text] [Related]

  • 5. A phase IB clinical and pharmacokinetic study of the angiogenesis inhibitor SU5416 and paclitaxel in recurrent or metastatic carcinoma of the head and neck.
    Cooney MM, Tserng KY, Makar V, McPeak RJ, Ingalls ST, Dowlati A, Overmoyer B, McCrae K, Ksenich P, Lavertu P, Ivy P, Hoppel CL, Remick S.
    Cancer Chemother Pharmacol; 2005 Mar 15; 55(3):295-300. PubMed ID: 15538570
    [Abstract] [Full Text] [Related]

  • 6. Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors.
    Eskens FA, Steeghs N, Verweij J, Bloem JL, Christensen O, van Doorn L, Ouwerkerk J, de Jonge MJ, Nortier JW, Kraetzschmar J, Rajagopalan P, Gelderblom H.
    J Clin Oncol; 2009 Sep 01; 27(25):4169-76. PubMed ID: 19636022
    [Abstract] [Full Text] [Related]

  • 7. Phase I trial of pazopanib in patients with advanced cancer.
    Hurwitz HI, Dowlati A, Saini S, Savage S, Suttle AB, Gibson DM, Hodge JP, Merkle EM, Pandite L.
    Clin Cancer Res; 2009 Jun 15; 15(12):4220-7. PubMed ID: 19509175
    [Abstract] [Full Text] [Related]

  • 8. A Phase I study of the angiogenesis inhibitor SU5416 (semaxanib) in solid tumours, incorporating dynamic contrast MR pharmacodynamic end points.
    O'Donnell A, Padhani A, Hayes C, Kakkar AJ, Leach M, Trigo JM, Scurr M, Raynaud F, Phillips S, Aherne W, Hardcastle A, Workman P, Hannah A, Judson I.
    Br J Cancer; 2005 Oct 17; 93(8):876-83. PubMed ID: 16222321
    [Abstract] [Full Text] [Related]

  • 9. A phase I study of the safety and pharmacokinetics of edotecarin (J-107088), a novel topoisomerase I inhibitor, in patients with advanced solid tumors.
    Hurwitz HI, Cohen RB, McGovren JP, Hirawat S, Petros WP, Natsumeda Y, Yoshinari T.
    Cancer Chemother Pharmacol; 2007 Jan 17; 59(1):139-47. PubMed ID: 16819636
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and toxicity of the angiogenesis inhibitor SU5416 as a single agent in patients with advanced renal cell carcinoma, melanoma, and soft tissue sarcoma.
    Kuenen BC, Tabernero J, Baselga J, Cavalli F, Pfanner E, Conte PF, Seeber S, Madhusudan S, Deplanque G, Huisman H, Scigalla P, Hoekman K, Harris AL.
    Clin Cancer Res; 2003 May 17; 9(5):1648-55. PubMed ID: 12738717
    [Abstract] [Full Text] [Related]

  • 11. Angiogenesis inhibition in solid tumors.
    Rosen LS.
    Cancer J; 2001 May 17; 7 Suppl 3():S120-8. PubMed ID: 11779082
    [Abstract] [Full Text] [Related]

  • 12. Dose-finding study of the multitargeted tyrosine kinase inhibitor SU6668 in patients with advanced malignancies.
    Kuenen BC, Giaccone G, Ruijter R, Kok A, Schalkwijk C, Hoekman K, Pinedo HM.
    Clin Cancer Res; 2005 Sep 01; 11(17):6240-6. PubMed ID: 16144927
    [Abstract] [Full Text] [Related]

  • 13. Novel Phase I dose de-escalation design trial to determine the biological modulatory dose of the antiangiogenic agent SU5416.
    Dowlati A, Robertson K, Radivoyevitch T, Waas J, Ziats NP, Hartman P, Abdul-Karim FW, Wasman JK, Jesberger J, Lewin J, McCrae K, Ivy P, Remick SC.
    Clin Cancer Res; 2005 Nov 01; 11(21):7938-44. PubMed ID: 16278419
    [Abstract] [Full Text] [Related]

  • 14. Phase II study of the Flk-1 tyrosine kinase inhibitor SU5416 in advanced melanoma.
    Peterson AC, Swiger S, Stadler WM, Medved M, Karczmar G, Gajewski TF.
    Clin Cancer Res; 2004 Jun 15; 10(12 Pt 1):4048-54. PubMed ID: 15217937
    [Abstract] [Full Text] [Related]

  • 15. Vascular endothelial growth factor-mediated angiogenesis inhibition and postoperative wound healing in rats.
    Roman CD, Choy H, Nanney L, Riordan C, Parman K, Johnson D, Beauchamp RD.
    J Surg Res; 2002 Jun 01; 105(1):43-7. PubMed ID: 12069500
    [Abstract] [Full Text] [Related]

  • 16. SU5416 and SU6668 attenuate the angiogenic effects of radiation-induced tumor cell growth factor production and amplify the direct anti-endothelial action of radiation in vitro.
    Abdollahi A, Lipson KE, Han X, Krempien R, Trinh T, Weber KJ, Hahnfeldt P, Hlatky L, Debus J, Howlett AR, Huber PE.
    Cancer Res; 2003 Jul 01; 63(13):3755-63. PubMed ID: 12839971
    [Abstract] [Full Text] [Related]

  • 17. Phase I study of antisense oligonucleotide against vascular endothelial growth factor: decrease in plasma vascular endothelial growth factor with potential clinical efficacy.
    Levine AM, Tulpule A, Quinn DI, Gorospe G, Smith DL, Hornor L, Boswell WD, Espina BM, Groshen SG, Masood R, Gill PS.
    J Clin Oncol; 2006 Apr 10; 24(11):1712-9. PubMed ID: 16520466
    [Abstract] [Full Text] [Related]

  • 18. A Phase I study of escalating doses of the tyrosine kinase inhibitor semaxanib (SU5416) in combination with irinotecan in patients with advanced colorectal carcinoma.
    Hoff PM, Wolff RA, Bogaard K, Waldrum S, Abbruzzese JL.
    Jpn J Clin Oncol; 2006 Feb 10; 36(2):100-3. PubMed ID: 16449240
    [Abstract] [Full Text] [Related]

  • 19. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy.
    Timke C, Zieher H, Roth A, Hauser K, Lipson KE, Weber KJ, Debus J, Abdollahi A, Huber PE.
    Clin Cancer Res; 2008 Apr 01; 14(7):2210-9. PubMed ID: 18381963
    [Abstract] [Full Text] [Related]

  • 20. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
    Murren J, Modiano M, Clairmont C, Lambert P, Savaraj N, Doyle T, Sznol M.
    Clin Cancer Res; 2003 Sep 15; 9(11):4092-100. PubMed ID: 14519631
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.